Johnson & Johnson (NYSE:JNJ) Shares Purchased by Hoey Investments Inc.

Hoey Investments Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 18.7% during the fourth quarter, Holdings Channel reports. The firm owned 2,413 shares of the company’s stock after acquiring an additional 380 shares during the quarter. Hoey Investments Inc.’s holdings in Johnson & Johnson were worth $349,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. IFS Advisors LLC lifted its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $32,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 19th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Trading Up 0.3 %

JNJ opened at $163.63 on Monday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The business’s 50 day moving average is $158.68 and its two-hundred day moving average is $156.07. The firm has a market cap of $394.32 billion, a price-to-earnings ratio of 24.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the company posted $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.03%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.